Coptis extracts enhance the anticancer effect of estrogen receptor antagonists on human breast cancer cells

Biochemical and Biophysical Research Communications

Volumn 378, Issue 2, 2009, Pages 174-178

  Liu, Jing ^a   He, Chengwei ^a,b   Zhou, Keyuan ^b   Wang, Jingdong ^a   Kang, Jing X ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b GUANGDONG MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Cell growth; Coptis; Estrogen receptor antagonist; Gene expression

Indexed keywords

ANTIESTROGEN; AROMATASE INHIBITOR; BERBERINE; BETA INTERFERON; COPTIS JAPONICA EXTRACT; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ANTAGONIST; FULVESTRANT; GOLD THREAD; PROTEIN BCL 2; PROTEIN P21; SELECTIVE ESTROGEN RECEPTOR MODULATOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CELL STRAIN; CELL STRAIN MCF 7; CELL STRAIN MDA MB 231; CONTROLLED STUDY; COPTIS; DRUG EFFICACY; DRUG POTENTIATION; GENE EXPRESSION REGULATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; MEDICINAL PLANT; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; COPTIS; ESTROGEN ANTAGONISTS; HUMANS; PLANT EXTRACTS; RECEPTORS, ESTROGEN;

COPTIS;

EID: 57049110383     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.10.169     Document Type: Article

References (25)

1. Jordan V.C. Tamoxifen: catalyst for the change to targeted therapy. Eur. J. Cancer 44 (2008) 30-38
2. Lee W.L., Cheng M.H., Chao H.T., and Wang P.H. The role of selective estrogen receptor modulators on breast cancer: from tamoxifen to raloxifene. Taiwan J. Obstet. Gynecol. 47 (2008) 24-31
3. Abukhdeir A.M., Vitolo M.I., Argani P., De Marzo A.M., Karakas B., Konishi H., Gustin J.P., Lauring J., Garay J.P., Pendleton C., Konishi Y., Blair B.G., Brenner K., Garrett-Mayer E., Carraway H., Bachman K.E., and Park B.H. Tamoxifen-stimulated growth of breast cancer due to p21 loss. Proc. Natl. Acad. Sci. USA 105 (2008) 288-293
4. Shou J., Massarweh S., Osborne C.K., Wakeling A.E., Ali S., Weiss H., and Schiff R. Mechanisms of tamoxifen resistance. increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J. Natl. Cancer Inst. 96 (2004) 926-935
5. Gutierrez M.C., Detre S., Johnston S., Mohsin S.K., Shou J., Allred D.C., Schiff R., Osborne C.K., and Dowsett M. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J. Clin. Oncol. 23 (2005) 2469-2476
6. Planas-Silva M.D., Bruggeman R.D., Grenko R.T., and Smith J.S. Overexpression of c-Myc and Bcl-2 during progression and distant metastasis of hormone-treated breast cancer. Exp. Mol. Pathol. 82 (2007) 85-90
7. Tari A.M., Simeone A.M., Li Y.J., Gutierrez-Puente Y., Lai S., and Symmans W.F. Cyclooxygenase-2 protein reduces tamoxifen and N-(4-hydroxyphenyl)retinamide inhibitory effects in breast cancer cells. Lab. Invest. 85 (2005) 1357-1367
8. Perey L., Paridaens R., Hawle H., Zaman K., Nole F., Wildiers H., Fiche M., Dietrich D., Clement P., Koberle D., Goldhirsch A., and Thurlimann B. Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). Ann. Oncol. 18 (2007) 64-69
9. Dowsett M., Nicholson R.I., and Pietras R.J. Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance. Breast Cancer Res. Treat. 93 1 Suppl. 1 (2005) S11-S18
10. Massarweh S., Osborne C.K., Jiang S., Wakeling A.E., Rimawi M., Mohsin S.K., Hilsenbeck S., and Schiff R. Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. Cancer Res. 66 (2006) 8266-8273
11. Hsieh Y.S., Kuo W.H., Lin T.W., Chang H.R., Lin T.H., Chen P.N., and Chu S.C. Protective effects of berberine against low-density lipoprotein (LDL) oxidation and oxidized LDL-induced cytotoxicity on endothelial cells. J. Agric. Food Chem. 55 (2007) 10437-10445
12. Iizuka N., Miyamoto K., Okita K., Tangoku A., Hayashi H., Yosino S., Abe T., Morioka T., Hazama S., and Oka M. Inhibitory effect of Coptidis Rhizoma and berberine on the proliferation of human esophageal cancer cell lines. Cancer Lett. 148 (2000) 19-25
13. Hara A., Hamamoto Y., Uchimura S., Miyamoto T., Tsunedomi R., Miyamoto K., Hazama S., Okita K., and Oka M. Molecular dissection of a medicinal herb with anti-tumor activity by oligonucleotide microarray. Life Sci. 77 (2005) 991-1002
14. Kuo C.L., Chi C.W., and Liu T.Y. Modulation of apoptosis by berberine through inhibition of cyclooxygenase-2 and Mcl-1 expression in oral cancer cells. In Vivo 19 (2005) 247-252
15. Hwang J.M., Kuo H.C., Tseng T.H., Liu J.Y., and Chu C.Y. Berberine induces apoptosis through a mitochondria/caspases pathway in human hepatoma cells. Arch. Toxicol. 80 (2006) 62-73
16. Kang J.X., Liu J., Wang J., He C., and Li F.P. The extract of huanglian, a medicinal herb, induces cell growth arrest and apoptosis by upregulation of interferon-beta and TNF-alpha in human breast cancer cells. Carcinogenesis 26 (2005) 1934-1939
17. Scudiero D.A., Paull K.D., Monks A., Tierney S., Nofziger T.H., Currens M.J., Seniff D., and Boyd M.R. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res. 48 (1988) 7
18. Koren R., Rocker D., Kotestiano O., Liberman U.A., and Ravid A. Synergistic anticancer activity of 1, 25-dihydroxyvitamin D(3) and immune cytokines: the involvement of reactive oxygen species. J. Steroid Biochem. Mol. Biol. 73 (2000) 105-112
19. Witters L.M., Witkoski A., Planas-Silva M.D., Berger M., Viallet J., and Lipton A. Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor. Oncol. Rep. 17 (2007) 465-469
20. Fox E.M., Bernaciak T.M., Wen J., Weaver A.M., Shupnik M.A., and Silva C.M. Signal transducer and activator of transcription 5b, C-Src, and epidermal growth factor receptor signaling play integral roles in estrogen-stimulated proliferation of estrogen receptor-positive breast cancer cells. Mol. Endocrinol. 22 (2008) 1781-1796
21. Kim R., Tanabe K., Emi M., Uchida Y., and Toge T. Modulation of tamoxifen sensitivity by antisense Bcl-2 and trastuzumab in breast carcinoma cells. Cancer 103 (2005) 2199-2207
22. Buzzi F., Brugia M., Rossi G., Giustini L., Scoponi C., and Sica G. Combination of beta-interferon and tamoxifen as a new way to overcome clinical resistance to tamoxifen in advanced breast cancer. Anticancer Res. 12 (1992) 869-871
23. Puntoni M., Marra D., Zanardi S., and Decensi A. Inflammation and cancer prevention. Ann. Oncol. 19 Suppl. 7 (2008) vii225-vii229
24. Hsieh T.C., and Wu J.M. Suppression of cell proliferation and gene expression by combinatorial synergy of EGCG, resveratrol and gamma-tocotrienol in estrogen receptor-positive MCF-7 breast cancer cells. Int. J. Oncol. 33 (2008) 851-859
25. Tortora G., Bianco R., Daniele G., Ciardiello F., McCubrey J.A., Ricciardi M.R., Ciuffreda L., Cognetti F., Tafuri A., and Milella M. Overcoming resistance to molecularly targeted anticancer therapies: rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. Drug Resist Updat. 10 (2007) 81-100